Education
About Us
Working with TipRanks
Follow Us
Aquestive Therapeutics (AQST)
NASDAQ:AQST
AQST Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.12 - $5.80
Previous CloseN/A
Volume606.88K
Average Volume (3M)1.11M
Market Cap
$379.43M
Enterprise Value$332.84M
Total Cash (Recent Filing)$68.66M
Total Debt (Recent Filing)$39.13M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Aug 11, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding99,327,930
10 Day Avg. Volume872,309
30 Day Avg. Volume1,112,767
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue6.14
Enterprise Value/Gross Profit8.97
Enterprise Value/Ebitda-9.41
Forecast
1Y Price Target
$6.96Price Target Upside82.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Commercial PotentialAnaphylm could generate peak sales of over $226M by 2035, indicating significant commercial potential.
Market ExpansionAquestive is making proactive efforts to lay the regulatory groundwork for Anaphylm’s international expansion beyond the US.
Regulatory ApprovalsManagement indicated that their interactions with the FDA have been smooth, which is a positive sign for the approval process.
Bears Say
Financial PerformanceManagement lowered full-year revenue guidance due to the FDA's revision of Libervant's regulatory status.
Legal UncertaintyThe recent US District Court Ruling for Libervant brings uncertainty to the program's future outlook on the US market.
Regulatory ChallengesPotential volatility in the stock could arise depending on whether the FDA decides to hold an advisory committee meeting for Anaphylm.
Aquestive Therapeutics News
AQST FAQ
What was Aquestive Therapeutics’s price range in the past 12 months?
Aquestive Therapeutics lowest stock price was $2.12 and its highest was $5.80 in the past 12 months.
What is Aquestive Therapeutics’s market cap?
Aquestive Therapeutics’s market cap is $379.43M.
When is Aquestive Therapeutics’s upcoming earnings report date?
Aquestive Therapeutics’s upcoming earnings report date is Aug 11, 2025 which is in 6 days.
How were Aquestive Therapeutics’s earnings last quarter?
Aquestive Therapeutics released its earnings results on May 12, 2025. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.165 by -$0.075.
Is Aquestive Therapeutics overvalued?
According to Wall Street analysts Aquestive Therapeutics’s price is currently Undervalued.
Does Aquestive Therapeutics pay dividends?
Aquestive Therapeutics does not currently pay dividends.
What is Aquestive Therapeutics’s EPS estimate?
Aquestive Therapeutics’s EPS estimate is -0.17.
How many shares outstanding does Aquestive Therapeutics have?
Aquestive Therapeutics has 99,327,930 shares outstanding.
What happened to Aquestive Therapeutics’s price movement after its last earnings report?
Aquestive Therapeutics reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.165. Following the earnings report the stock price went down -19.649%.
Which hedge fund is a major shareholder of Aquestive Therapeutics?
Currently, no hedge funds are holding shares in AQST
Aquestive Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.96 (82.20% Upside)
$6.96 (82.20% Upside)
Blogger Sentiment
Bullish
AQST Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 3.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.0%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.40%
12-Months-Change
Fundamentals
Return on Equity
77.48%
Trailing 12-Months
Asset Growth
-21.07%
Trailing 12-Months
Company Description
Aquestive Therapeutics
Aquestive Therapeutics, Inc. (AQST) is a specialty pharmaceutical company focused on developing and commercializing innovative products to address unmet needs in the treatment of central nervous system (CNS) disorders and other therapeutic areas. The company specializes in the creation of orally administered therapeutics using its proprietary PharmFilm® technology, which delivers medication through thin, dissolvable films. Aquestive's portfolio includes FDA-approved products as well as a robust pipeline of development-stage candidates aimed at enhancing patient care and improving therapeutic outcomes.
AQST Company Deck
AQST Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook. While there was significant progress in the FDA review and commercial readiness for Anaphylm, the company faced substantial revenue declines and increased losses. The anticipation of Anaphylm's market entry and strategic preparations provide optimism, but financial challenges persist.Read More>AQST Stock 12 Month Forecast
Average Price Target
$6.96
▲(82.20%Upside)
Technical Analysis
Emergent Biosolutions
―
Lifecore Biomedical
―
Rockwell Med
―
Esperion
―
Journey Medical Corp
―
Ownership Overview
13.67% Insiders
6.40% Mutual Funds
20.31% Other Institutional Investors
51.88% Public Companies and
Individual Investors